A tRial Evaluating Mid cut-Off Value membrane clearance of Albumin and Light chains in HaemoDialysis patients
Principal Investigator: Dr Colin Hutchison
The REMOVAL-HD Study includes haemodialysis patients with AV fistula or graft and aims to use Theranova dialysers to increase the removal of the larger middle-molecules without decrease in serum albumin. The study is a single armed, open label, pivotal device trial and the primary outcome is change in pre-dialysis concentration of serum albumin between baseline and six months. The study has an Investigator Initiated Research (IIR) Grant of US $250,000 provided by Baxter Healthcare Corporation and the recruitment target is 85 patients in eight sites in Australia and New Zealand.